Tenaya Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.3984 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 89.33M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection ...